NMRD Key Statistics, Chart & Performance
The current stock price of NMRD is 0.1053 USD. In the past month the price decreased by -54.22%. In the past year, price decreased by -94.2%.
NMRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.96 | 216.56B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.05 | 204.67B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.57 | 142.45B | ||
| SYK | STRYKER CORP | 26.94 | 135.69B | ||
| BDX | BECTON DICKINSON AND CO | 13.57 | 55.85B | ||
| IDXX | IDEXX LABORATORIES INC | 54.11 | 54.48B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.55 | 50.04B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.15 | 37.95B | ||
| RMD | RESMED INC | 24.71 | 35.70B | ||
| DXCM | DEXCOM INC | 35.95 | 26.08B | ||
| PODD | INSULET CORP | 62.47 | 20.08B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.05 | 17.72B |
Related stock screener links
About NMRD
Company Profile
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Company Info
NEMAURA MEDICAL INC
57 W 57th St
New York City NEW YORK 10019 US
CEO: Dewan Fazlul Hoque Chowdhury
Employees: 36
NEMAURA MEDICAL INC / NMRD FAQ
Can you describe the business of NEMAURA MEDICAL INC?
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
What is the stock price of NEMAURA MEDICAL INC today?
The current stock price of NMRD is 0.1053 USD. The price decreased by -17.8% in the last trading session.
What is the dividend status of NEMAURA MEDICAL INC?
NMRD does not pay a dividend.
How is the ChartMill rating for NEMAURA MEDICAL INC?
NMRD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists NMRD stock?
NMRD stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of NEMAURA MEDICAL INC (NMRD)?
NEMAURA MEDICAL INC (NMRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
How many employees does NEMAURA MEDICAL INC have?
NEMAURA MEDICAL INC (NMRD) currently has 36 employees.
NMRD Technical Analysis
NMRD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRD. NMRD may be in some trouble as it scores bad on both profitability and health.
NMRD Financial Highlights
Over the last trailing twelve months NMRD reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 39.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMRD Forecast & Estimates
7 analysts have analysed NMRD and the average price target is 8.67 USD. This implies a price increase of 8133.62% is expected in the next year compared to the current price of 0.1053.
For the next year, analysts expect an EPS growth of 42.95% and a revenue growth 43.63% for NMRD